Related references
Note: Only part of the references are listed.Guidelines on the diagnosis and management of Waldenstrom macroglobulinaemia-A British Society for Haematology guideline
Guy Pratt et al.
BRITISH JOURNAL OF HAEMATOLOGY (2022)
Preneoplastic somatic mutations including MYD88L265P in lymphoplasmacytic lymphoma
Sara Rodriguez et al.
SCIENCE ADVANCES (2022)
Determination of MYD88L265P mutation fraction in IgM monoclonal gammopathies
Tina Bagratuni et al.
BLOOD ADVANCES (2022)
6q deletion in Waldenstrom macroglobulinaemia negatively affects time to transformation and survival
Ramon Garcia-Sanz et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenstrom Macroglobulinemia
Steven P. Treon et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Waldenstrom's Macroglobulinemia: An Exploration into the Pathology and Diagnosis of a Complex B-Cell Malignancy
Elham Askari et al.
JOURNAL OF BLOOD MEDICINE (2021)
Waldenstrom macroglobulinemia: 2021 update on diagnosis, risk stratification, and management
Morie A. Gertz
AMERICAN JOURNAL OF HEMATOLOGY (2021)
CXCR4 in Waldenstrom's Macroglobulinema: chances and challenges
Lisa Marie Kaiser et al.
LEUKEMIA (2021)
Epigenetic targeting of Waldenstrom macroglobulinemia cells with BET inhibitors synergizes with BCL2 or histone deacetylase inhibition
Stephan J. Matissek et al.
EPIGENOMICS (2021)
Bone marrow involvement and subclonal diversity impairs detection of mutated CXCR4 by diagnostic next-generation sequencing in Waldenstrom macroglobulinaemia
Joshua N. Gustine et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Circulating RNA biomarkers in diffuse large B-cell lymphoma: a systematic review
Philippe Decruyenaere et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2021)
Cell-free DNA analysis for detection of MYD88L265P and CXCR4S338X mutations in Waldenstrom macroglobulinemia
Maria G. Demos et al.
AMERICAN JOURNAL OF HEMATOLOGY (2021)
MyD88 oligomer size functions as a physical threshold to trigger IL1R Myddosome signaling
Rafael Deliz-Aguirre et al.
JOURNAL OF CELL BIOLOGY (2021)
Monoclonal Gammopathy of Renal Significance
Nelson Leung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
CircRNAs: role in human diseases and potential use as biomarkers
Lorena Verduci et al.
CELL DEATH & DISEASE (2021)
Liquid Biopsy: From Discovery to Clinical Application
Catherine Alix-Panabieres et al.
CANCER DISCOVERY (2021)
Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenstrom macroglobulinemia
Yingjun Wang et al.
NEOPLASIA (2021)
Identification of a Candidate Gene Set Signature for the Risk of Progression in IgM MGUS to Smoldering/Symptomatic Waldenstrom Macroglobulinemia (WM) by a Comparative Transcriptome Analysis of B Cells and Plasma Cells
Alessandra Trojani et al.
CANCERS (2021)
MYD88L265P Detection in IgM Monoclonal Gammopathies: Methodological Considerations for Routine Implementation
Martina Ferrante et al.
DIAGNOSTICS (2021)
Cytogenetic and molecular abnormalities in Waldenstrom's macroglobulinemia patients: Correlations and prognostic impact
Daphne Krzisch et al.
AMERICAN JOURNAL OF HEMATOLOGY (2021)
Liquid Biopsy: Blood-Based Analyses of ctDNA and CTCs
Klaus Pantel
CLINICAL CHEMISTRY (2021)
Liquid biopsy in extranodal NK/T-cell lymphoma: a prospective analysis of cell-free DNA genotyping and monitoring
Fei Qi et al.
BLOOD ADVANCES (2021)
Diagnostic Next-generation Sequencing Frequently Fails to Detect MYD88L265P in Waldenstrom Macroglobulinemia
Amanda Kofides et al.
HEMASPHERE (2021)
IgM paraprotein-associated peripheral neuropathy: small CD20-positive B-cell clones may predict a monoclonal gammopathy of neurological significance and rituximab responsiveness
Lucia Y. Chen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Circ-RPL15: a plasma circular RNA as novel oncogenic driver to promote progression of chronic lymphocytic leukemia
Zijuan Wu et al.
LEUKEMIA (2020)
Genomic Landscape of Waldenstrom Macroglobulinemia and Its Impact on Treatment Strategies
Steven P. Treon et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
A practical guide to laboratory investigations at diagnosis and follow up in Waldenstrom macroglobulinaemia: recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Sub-committee of the Lymphoma and Related Diseases Registry and the Australasian Association of Clinical Biochemists Monoclonal Gammopathy Working Group
M. Gohar Maqbool et al.
PATHOLOGY (2020)
Cell-free DNA analysis for the detection of MYD88 and CXCR4 mutations in IgM monoclonal gammopathies; an update with clinicopathological correlations
Ioannis Ntanasis-Stathopoulos et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Acalabrutinib monotherapy in patients with Waldenstrom macroglobulinemia: a single-arm, multicentre, phase 2 study
Roger G. Owen et al.
LANCET HAEMATOLOGY (2020)
Single-molecule analysis of nucleic acid biomarkers - A review
Tal Gilboa et al.
ANALYTICA CHIMICA ACTA (2020)
Detection of the MYD88L265P and CXCR4S338X mutations by cell-free DNA in Waldenstrom macroglobulinemia
Yan-Yan Wu et al.
ANNALS OF HEMATOLOGY (2020)
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstrom macroglobulinemia: the ASPEN study
Constantine S. Tam et al.
BLOOD (2020)
Aberrant CXCR4 Signaling at Crossroad of WHIM Syndrome and Waldenstrom's Macroglobulinemia
Samantha Milanesi et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Precision Prevention and Cancer Interception: The New Challenges of Liquid Biopsy
Maria Jose Serrano et al.
CANCER DISCOVERY (2020)
Comparative genomics of CXCR4MUT and CXCR4WT single cells in Waldenstrom's macroglobulinemia
Cristina Jimenez et al.
BLOOD ADVANCES (2020)
B-Cell-Specific Myd88 L252P Expression Causes a Premalignant Gammopathy Resembling IgM MGUS
Kristin Schmidt et al.
FRONTIERS IN IMMUNOLOGY (2020)
Zanubrutinib for the treatment of MYD88 wild-type Waldenstrom macroglobulinemia: a substudy of the phase 3 ASPEN trial
Meletios Dimopoulos et al.
BLOOD ADVANCES (2020)
MYD88 and CXCR4 Mutation Profiling in Lymphoplasmacytic Lymphoma/Waldenstrom's Macroglobulinaemia
Sushant Vinarkar et al.
INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION (2019)
MYD88 and CXCR4 Mutation Profiling in Lymphoplasmacytic Lymphoma/Waldenstrom's Macroglobulinaemia
Sushant Vinarkar et al.
INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION (2019)
TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenstrom macroglobulinaemia
Joshua N. Gustine et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Understanding early TLR signaling through the Myddosome
Katherine R. Balka et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2019)
Innate Immune Signaling Organelles Display Natural and Programmable Signaling Flexibility
Yunhao Tan et al.
CELL (2019)
CircRNA circ_0000190 inhibits the progression of multiple myeloma through modulating miR-767-5p/MAPK4 pathway
Yashu Feng et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
The circulating transcriptome as a source of cancer liquid biopsy biomarkers
Carla Sole et al.
SEMINARS IN CANCER BIOLOGY (2019)
LncRNA H19 overexpression induces bortezomib resistance in multiple myeloma by targeting MCL-1 via miR-29b-3p
Yafang Pan et al.
CELL DEATH & DISEASE (2019)
A revised international prognostic score system for Waldenstrom's macroglobulinemia
Efstathios Kastritis et al.
LEUKEMIA (2019)
A Recurrent Activating Missense Mutation in Waldenstrom Macroglobulinemia Affects the DNA Binding of the ETS Transcription Factor SPI1 and Enhances Proliferation
Damien Roos-Weil et al.
CANCER DISCOVERY (2019)
Downregulation of circ_0132266 in chronic lymphocytic leukemia promoted cell viability through miR-337-3p/PML axis
Wei Wu et al.
AGING-US (2019)
CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenstrom macroglobulinaemia treated with ibrutinib
Jorge J. Castillo et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
CXCR4 mutations affect presentation and outcomes in patients with Waldenstrom macroglobulinemia: A systematic review
Jorge J. Castillo et al.
EXPERT REVIEW OF HEMATOLOGY (2019)
The biogenesis, biology and characterization of circular RNAs
Lasse S. Kristensen et al.
NATURE REVIEWS GENETICS (2019)
Detection of MYD88 L265P mutation by next-generation deep sequencing in peripheral blood mononuclear cells of Waldenstrom's macroglobulinemia and IgM monoclonal gammopathy of undetermined significance
Ayako Nakamura et al.
PLOS ONE (2019)
Circ-SMARCA5 suppresses progression of multiple myeloma by targeting miR-767-5p
Haiyan Liu et al.
BMC CANCER (2019)
Human MYD88L265P is insufficient by itself to drive neoplastic transformation in mature mouse B cells
Tomasz Sewastianik et al.
BLOOD ADVANCES (2019)
Unraveling the heterogeneity of IgM monoclonal gammopathies: a gene mutational and gene expression study
Cristina Jimenez et al.
ANNALS OF HEMATOLOGY (2018)
Circular RNA circ-CBFB promotes proliferation and inhibits apoptosis in chronic lymphocytic leukemia through regulating miR-607/FZD3/Wnt/β-catenin pathway
Liang Xia et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2018)
Extracellular vesicle-mediated transfer of constitutively active MyD88L265P engages MyD88wt and activates signaling
Mateja Mancek-Keber et al.
BLOOD (2018)
Serum level of long noncoding RNA H19 as a diagnostic biomarker of multiple myeloma
Yafang Pan et al.
CLINICA CHIMICA ACTA (2018)
MYD88 mutated and wild-type Waldenstrom's Macroglobulinemia: characterization of chromosome 6q gene losses and their mutual exclusivity with mutations in CXCR4
Maria Luisa Guerrera et al.
HAEMATOLOGICA (2018)
Highly sensitive MYD88(L265P) mutation detection by droplet digital polymerase chain reaction in Waldenstrom macroglobulinemia
Daniela Drandi et al.
HAEMATOLOGICA (2018)
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
Christian Rolfo et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies
Tina Bagratuni et al.
LEUKEMIA (2018)
Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance
Robert A. Kyle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
MYD88 mutated and wild-type Waldenstrom's Macroglobulinemia: characterization of chromosome 6q gene losses and their mutual exclusivity with mutations in CXCR4
Maria Luisa Guerrera et al.
HAEMATOLOGICA (2018)
Highly sensitive MYD88(L265P) mutation detection by droplet digital polymerase chain reaction in Waldenstrom macroglobulinemia
Daniela Drandi et al.
HAEMATOLOGICA (2018)
Blood-Based Cancer Biomarkers in Liquid Biopsy: A Promising Non-Invasive Alternative to Tissue Biopsy
Jose Marrugo-Ramirez et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Enzyme-free digital counting of endogenous circular RNA molecules in B-cell malignancies
Mette Dahl et al.
LABORATORY INVESTIGATION (2018)
Profiling of circulating exosomal miRNAs in patients with Waldenstrom Macroglobulinemia
Juliette M. Bouyssou et al.
PLOS ONE (2018)
Pathological mutations differentially affect the self-assembly and polymerisation of the innate immune system signalling adaptor molecule MyD88
Ailis O'Carroll et al.
BMC BIOLOGY (2018)
Gene Expression Profile Signature of Aggressive Waldenstrom Macroglobulinemia with Chromosome 6q Deletion
Naohiro Sekiguchi et al.
BIOMED RESEARCH INTERNATIONAL (2018)
Insights into the genomic landscape of MYD88 wild-type Waldenstrom macroglobulinemia
Zachary R. Hunter et al.
BLOOD ADVANCES (2018)
MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, andoverall survival
Steven P. Treon et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
MYD88 mutation status does not impact overall survival in Waldenstrom macroglobulinemia
Jithma P. Abeykoon et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
To select or not to select? The role of B-cell selection in determining the MYD88 mutation status in Waldenstrom Macroglobulinaemia
Joshua Gustine et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Prevalence and prognosis implication of MYD88 L265P mutation in IgM monoclonal gammopathy of undetermined significance and smouldering Waldenstrom macroglobulinaemia
Juan G. Correa et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Genetic characterization of MYD88-mutated lymphoplasmacytic lymphoma in comparison with MYD88-mutated chronic lymphocytic leukemia
C. Baer et al.
LEUKEMIA (2017)
MicroRNA-155 in serum-derived extracellular vesicles as a potential biomarker for hematologic malignancies - a short report
Antonella Caivano et al.
CELLULAR ONCOLOGY (2017)
Pattern of somatic mutations in patients with Waldenstrom macroglobulinemia or IgM monoclonal gammopathy of undetermined significance
Marzia Varettoni et al.
HAEMATOLOGICA (2017)
MYD88 L265P mutation in cutaneous involvement by Waldenstrom macroglobulinemia
Victoria Alegria-Landa et al.
JOURNAL OF CUTANEOUS PATHOLOGY (2017)
Integrating liquid biopsies into the management of cancer
Giulia Siravegna et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
LncRNA-mediated regulation of cell signaling in cancer
W-X Peng et al.
ONCOGENE (2017)
Circulating tumour DNA reflects treatment response and clonal evolution in chronic lymphocytic leukaemia
Paul Yeh et al.
NATURE COMMUNICATIONS (2017)
From Waldenstrom's macroglobulinemia to aggressive diffuse large B-cell lymphoma: a whole-exome analysis of abnormalities leading to transformation
C. Jimenez et al.
BLOOD CANCER JOURNAL (2017)
Pattern of somatic mutations in patients with Waldenstrom macroglobulinemia or IgM monoclonal gammopathy of undetermined significance
Marzia Varettoni et al.
HAEMATOLOGICA (2017)
Diagnosis and Management of Waldenstrom Macroglobulinemia Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016
Prashant Kapoor et al.
JAMA ONCOLOGY (2017)
TP53 Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia
Stephanie Poulain et al.
CLINICAL CANCER RESEARCH (2017)
Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naive patients with Waldenstrom macroglobulinemia
Jonas Paludo et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Evaluation of MiR-15a and MiR-16-1 as prognostic biomarkers in chronic lymphocytic leukemia
Tatiane Vieira Braga et al.
BIOMEDICINE & PHARMACOTHERAPY (2017)
Long Noncoding RNA and Cancer: A New Paradigm
Arunoday Bhan et al.
CANCER RESEARCH (2017)
Detection of MYD88 L265P and WHIM-like CXCR4 mutation in patients with IgM monoclonal gammopathy related disease
Xin-xin Cao et al.
ANNALS OF HEMATOLOGY (2017)
Diffuse large B-cell lymphoma genotyping on the liquid biopsy
Davide Rossi et al.
BLOOD (2017)
Clonal architecture of CXCR4 WHIM-like mutations in Waldenstrom Macroglobulinaemia
Lian Xu et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Genomic Landscape of CXCR4 Mutations in Waldenstrom Macroglobulinemia
Stephanie Poulain et al.
CLINICAL CANCER RESEARCH (2016)
Low expression of pro-apoptotic Bcl-2 family proteins sets the apoptotic threshold in Waldenstrom macroglobulinemia
B. T. Gaudette et al.
ONCOGENE (2016)
Bone marrow microenvironment in Waldenstrom's Macroglobulinemia
Shahrzad Jalali et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2016)
HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib
Guang Yang et al.
BLOOD (2016)
Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenstrom macroglobulinemia
Zachary R. Hunter et al.
BLOOD (2016)
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Steven H. Swerdlow et al.
BLOOD (2016)
Clinical Validation of a CXCR4 Mutation Screening Assay for Waldenstrom Macroglobulinemia
Leomar Y. Ballester et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2016)
CXCR4 signaling in health and disease
Tommaso Pozzobon et al.
IMMUNOLOGY LETTERS (2016)
miR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growth
M. Fulciniti et al.
BLOOD CANCER JOURNAL (2016)
lncRNA profiling in early-stage chronic lymphocytic leukemia identifies transcriptional fingerprints with relevance in clinical outcome
D. Ronchetti et al.
BLOOD CANCER JOURNAL (2016)
Distinct lncRNA transcriptional fingerprints characterize progressive stages of multiple myeloma
Domenica Ronchetti et al.
ONCOTARGET (2016)
Epigenetic silencing of tumor suppressor long non-coding RNA BM742401 in chronic lymphocytic leukemia
Lu Qian Wang et al.
ONCOTARGET (2016)
Upregulation of long noncoding RNA MIAT in aggressive form of chronic lymphocytic leukemias
Arash Sattari et al.
ONCOTARGET (2016)
Detection of MYD88 L265P in patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia and other B-cell non- Hodgkin lymphomas
Sang-Yong Shin et al.
BLOOD RESEARCH (2016)
Combination of serum microRNA-320a and microRNA-320b as a marker for Waldenstrom macroglobulinemia
Lenka Kubiczkova Besse et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Innate Immune Pattern Recognition: A Cell Biological Perspective
Sky W. Brubaker et al.
ANNUAL REVIEW OF IMMUNOLOGY VOL 33 (2015)
The cellular origin and malignant transformation of Waldenstrom macroglobulinemia
Bruno Paiva et al.
BLOOD (2015)
MYD88 L265P and CXCR4 mutations in lymphoplasmacytic lymphoma identify cases with high disease activity
Janine Schmidt et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Modulation of the IL-6 Receptor a Underlies GLI2-Mediated Regulation of Ig Secretion in Waldenstrom Macroglobulinemia Cells
David A. Jackson et al.
JOURNAL OF IMMUNOLOGY (2015)
Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study
Mark Roschewski et al.
LANCET ONCOLOGY (2015)
p53-dependent non-coding RNA networks in chronic lymphocytic leukemia
C. J. Blume et al.
LEUKEMIA (2015)
Ibrutinib in Previously Treated Waldenstrom's Macroglobulinemia
Steven P. Treon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Upregulation of lncRNA MEG3 Promotes Osteogenic Differentiation of Mesenchymal Stem Cells From Multiple Myeloma Patients By Targeting BMP4 Transcription
Wenzhuo Zhuang et al.
STEM CELLS (2015)
High serum levels of extracellular vesicles expressing malignancy-related markers are released in patients with various types of hematological neoplastic disorders
Antonella Caivano et al.
TUMOR BIOLOGY (2015)
miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies
Nicola Amodio et al.
ONCOTARGET (2015)
The WHIM-like CXCR4S338X somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia
Y. Cao et al.
LEUKEMIA (2015)
MYD88 mutant lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia has distinct clinical and pathological features as compared to its mutation negative counterpart
Nikhil Patkar et al.
LEUKEMIA & LYMPHOMA (2015)
The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis
Zachary R. Hunter et al.
BLOOD (2014)
C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma
Aldo M. Roccaro et al.
BLOOD (2014)
Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia
Steven P. Treon et al.
BLOOD (2014)
MYD88 L265P mutation contributes to the diagnosis of Bing Neel syndrome
Stephanie Poulain et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Cancer Exosomes Perform Cell-Independent MicroRNA Biogenesis and Promote Tumorigenesis
Sonia A. Melo et al.
CANCER CELL (2014)
Double-stranded DNA in exosomes: a novel biomarker in cancer detection
Caitlin Williams et al.
CELL RESEARCH (2014)
Investigation of circulating lncRNAs in B-cell neoplasms
Mustafa Isin et al.
CLINICA CHIMICA ACTA (2014)
Detection of MYD88 L265P mutations in formalin-fixed and decalcified BM biopsies from patients with lymphoplasmacytic lymphoma
Ianina Belen Capaldi et al.
EXPERIMENTAL AND MOLECULAR PATHOLOGY (2014)
Consequences of the recurrent MYD88L265P somatic mutation for B cell tolerance
James Q. Wang et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
S. Vincent Rajkumar et al.
LANCET ONCOLOGY (2014)
Rapid detection of MYD88-L265P mutation by PCR-RFLP in B-cell lymphoproliferative disorders
N. Argentou et al.
LEUKEMIA (2014)
Detection of MYD88 L265P in peripheral blood of patients with Waldenstrom's Macroglobulinemia and IgM monoclonal gammopathy of undetermined significance
L. Xu et al.
LEUKEMIA (2014)
Activation of TAK1 by MYD88 L265P drives malignant B-cell Growth in non-Hodgkin lymphoma
S. M. Ansell et al.
BLOOD CANCER JOURNAL (2014)
Clonotypic Analysis of Immunoglobulin Heavy Chain Sequences in Patients with Waldenstrom's Macroglobulinemia: Correlation with MYD88 L265P Somatic Mutation Status, Clinical Features, and Outcome
Loizos Petrikkos et al.
BIOMED RESEARCH INTERNATIONAL (2014)
SMOCs: supramolecular organizing centres that control innate immunity
Jonathan C. Kagan et al.
NATURE REVIEWS IMMUNOLOGY (2014)
MYD88 L265P Somatic Mutation Its Usefulness in the Differential Diagnosis of Bone Marrow Involvement by B-Cell Lymphoproliferative Disorders
Sarah L. Ondrejka et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2013)
Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenstrom macroglobulinemia
Irene M. Ghobrial et al.
BLOOD (2013)
MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance
Marzia Varettoni et al.
BLOOD (2013)
MYD88 L265P mutation in Waldenstrom macroglobulinemia
Stephanie Poulain et al.
BLOOD (2013)
Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms
Marzia Varettoni et al.
BLOOD (2013)
MYD88 L265P in Waldenstrom macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction
Lian Xu et al.
BLOOD (2013)
Improved accuracy of discrimination between IgM Multiple Myeloma and Waldenstrom Macroglobulinaemia by testing for MYD88 L265P mutations
Wolfgang Willenbacher et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Microarray Demonstrates Different Gene Expression Profiling Signatures Between Waldenstrom Macroglobulinemia and IgM Monoclonal Gammopathy of Undetermined Significance
Alessandra Trojani et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2013)
Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenstrom's macroglobulinemia
Florence Nguyen-Khac et al.
HAEMATOLOGICA (2013)
IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenstrom macroglobulinemia/lymphoplasmacytic lymphomas
N. Gachard et al.
LEUKEMIA (2013)
MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenstrom's macroglobulinemia
C. Jimenez et al.
LEUKEMIA (2013)
L265P Mutation of the MYD88 Gene Is Frequent in Waldenstrom's Macroglobulinemia and Its Absence in Myeloma
Naoki Mori et al.
PLOS ONE (2013)
Epigenetic Upregulation of IncRNAs at 13q14.3 in Leukemia Is Linked to the In Cis Downregulation of a Gene Cluster That Targets NF-kB
Angela Garding et al.
PLOS GENETICS (2013)
Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia
Deepa Sampath et al.
BLOOD (2012)
Progression in smoldering Waldenstrom macroglobulinemia: long-term results
Robert A. Kyle et al.
BLOOD (2012)
LNA-mediated anti-miR-155 silencing in low-grade B-cell lymphomas
Yong Zhang et al.
BLOOD (2012)
Mechanisms of Activity of the TORC1 Inhibitor Everolimus in Waldenstrom Macroglobulinemia
Aldo M. Roccaro et al.
CLINICAL CANCER RESEARCH (2012)
Molecular pathogenesis of Waldenstrom's macroglobulinemia
Esteban Braggio et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Personalized medicine using DNA biomarkers: a review
Andreas Ziegler et al.
HUMAN GENETICS (2012)
MYD88 L265P Somatic Mutation in Waldenstrom's Macroglobulinemia
Steven P. Treon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity
Sherine F. Elsawa et al.
BLOOD (2011)
The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications
Elias Campo et al.
BLOOD (2011)
Factors Predicting Transformation of Asymptomatic IgM Monoclonal Gammopathy
Antonino Greco et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2011)
High-Throughput Genomic Analysis in Waldenstrom's Macroglobulinemia
Stephanie Poulain et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2011)
Histone Deacetylase Inhibitors Demonstrate Significant Preclinical Activity as Single Agents, and in Combination with Bortezomib in Waldenstrom's Macroglobulinemia
Jenny Y. Sun et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2011)
Non-coding RNAs in human disease
Manel Esteller
NATURE REVIEWS GENETICS (2011)
MicroRNA expression in tumor cells from Waldenstrom's macroglobulinemia reflects both their normal and malignant cell counterparts
L. S. Hodge et al.
BLOOD CANCER JOURNAL (2011)
microRNA-dependent modulation of histone acetylation in Waldenstrom macroglobulinemia
Aldo M. Roccaro et al.
BLOOD (2010)
Microrna let-7: an emerging next-generation cancer therapeutic
D. Barh et al.
Current Oncology (2010)
Diagnosis and Management of Waldenstrom Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines
Stephen M. Ansell et al.
MAYO CLINIC PROCEEDINGS (2010)
microRNA expression in the biology, prognosis, and therapy of Waldenstrom macroglobulinemia
Aldo M. Roccaro et al.
BLOOD (2009)
International prognostic scoring system for Waldenstrom macroglobulinemia
Pierre Morel et al.
BLOOD (2009)
MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma
Aldo M. Roccaro et al.
BLOOD (2009)
Identification of Copy Number Abnormalities and Inactivating Mutations in Two Negative Regulators of Nuclear Factor-κB Signaling Pathways in Waldenstrom's Macroglobulinemia
Esteban Braggio et al.
CANCER RESEARCH (2009)
Onco-miR-155 targets SHIP1 to promote TNFα-dependent growth of B cell lymphomas
Irene M. Pedersen et al.
EMBO MOLECULAR MEDICINE (2009)
Novel immunophenotypic features of marrow lymphoplasmacytic lymphoma and correlation with Waldenstrom's macroglobulinemia
William G. Morice et al.
MODERN PATHOLOGY (2009)
Long non-coding RNAs: insights into functions
Tim R. Mercer et al.
NATURE REVIEWS GENETICS (2009)
Prognostic Relevance of 6q Deletion in Waldenstrom's Macroglobulinemia: A Multicenter Study
Hong Chang et al.
CLINICAL LYMPHOMA & MYELOMA (2009)
Targeting NF-κB in Waldenstrom macroglobulinemia
Xavier Leleu et al.
BLOOD (2008)
Molecular origins of cancer: Epigenetics in cancer
Manel Esteller
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Gene expression profiling of B lymphocytes and plasma cells from Waldenstrom's macroglobulinemia:: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals
N. C. Gutierrez et al.
LEUKEMIA (2007)
6q deletion in Waldenstrom macroglobulinemia is associated with features of adverse prognosis
E. M. Ocio et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma
Wee J. Chng et al.
BLOOD (2006)
Genomewide linkage screen for Waldenstrom macroglobulinemia susceptibility loci in high-risk families
Mary L. McMaster et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2006)
6q deletion discriminates Waldenstrom macroglobulinemia from IgM monoclonal gammopathy of undetermined significance
Roelandt F. J. Schop et al.
CANCER GENETICS AND CYTOGENETICS (2006)
The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: Interplay of growth factors, their receptors and stromal interactions
Constantine S. Mitsiades et al.
EUROPEAN JOURNAL OF CANCER (2006)
Epigenetics provides a new generation of oncogenes and tumour-suppressor genes
M Esteller
BRITISH JOURNAL OF CANCER (2006)
Trisomy 4, a new chromosomal abnormality in Waldenstrom's macroglobulinemia: a study of 39 cases
C. Terre et al.
LEUKEMIA (2006)
BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas
J Kluiver et al.
JOURNAL OF PATHOLOGY (2005)
Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: Proposal for a common prognostic scoring system
L Baldini et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Accumulation of miR-155 and BIC RNA in human B cell lymphomas
PS Eis et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Prognostic factors for transformation in asymptomatic immunoglobulin M monoclonal gammopathies
E Morra et al.
CLINICAL LYMPHOMA (2005)
Clonotypic IgM V/D/J sequence analysis in Waldenstrom macroglobulinemia suggests an unusual B-cell origin and an expansion of polyclonal B cells in peripheral blood
J Kriangkum et al.
BLOOD (2004)
Despite apparent morphologic and immunophenotypic heterogeneity, Waldenstrom's macroglobulinemia is consistently composed of cells along a morphologic continuum of small lymphocytes, plasmacytoid lymphocytes, and plasma cells
ED Remstein et al.
SEMINARS IN ONCOLOGY (2003)
Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus panel recommendations from the second international workshop on Waldenstrom's macroglobulinemia
RG Owen et al.
SEMINARS IN ONCOLOGY (2003)
Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells
U Klein et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2001)
Serum levels of IL-6 and its soluble receptor (sIL-6R) in Waldenstrom's macroglobulinemia
EC Hatzimichael et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2001)
Share Paper
